These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31462137)

  • 1. The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy.
    Tjokrowidjaja A; Goldstein D; Hudson HM; Lord SJ; Gebski V; Clarke S; de Souza P; Motzer RJ; Lee CK
    Acta Oncol; 2020 Jan; 59(1):20-27. PubMed ID: 31462137
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy.
    Takagi T; Fukuda H; Kondo T; Ishihara H; Yoshida K; Kobayashi H; Iizuka J; Okumi M; Ishida H; Tanabe K
    Target Oncol; 2019 Apr; 14(2):179-186. PubMed ID: 30927174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy.
    Peyton CC; Abel EJ; Chipollini J; Boulware DC; Azizi M; Karam JA; Margulis V; Master VA; Matin SF; Raman JD; Sexton WJ; Wood CG; Spiess PE
    Eur Urol Focus; 2020 Jan; 6(1):104-111. PubMed ID: 30206003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporating Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Place of Neutrophil Count and Platelet Count Improves Prognostic Accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium Model.
    Chrom P; Stec R; Bodnar L; Szczylik C
    Cancer Res Treat; 2018 Jan; 50(1):103-110. PubMed ID: 28253564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.
    Tanaka N; Mizuno R; Yasumizu Y; Ito K; Shirotake S; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Oya M
    Urol Oncol; 2017 Feb; 35(2):39.e19-39.e28. PubMed ID: 27825515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy.
    Jeyakumar G; Kim S; Bumma N; Landry C; Silski C; Suisham S; Dickow B; Heath E; Fontana J; Vaishampayan U
    J Immunother Cancer; 2017 Oct; 5(1):82. PubMed ID: 29041991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy.
    Tamura K; Ando R; Takahara K; Ito T; Kanao K; Yasui T; Shiroki R; Miyake H
    Urol Oncol; 2021 Jan; 39(1):78.e1-78.e8. PubMed ID: 32958444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Patients with Metastatic Renal Cell Carcinoma.
    Parosanu AI; Pirlog CF; Slavu CO; Stanciu IM; Cotan HT; Vrabie RC; Popa AM; Olaru M; Iaciu C; Bratu LI; Baicoianu IF; Moldoveanu O; Baston C; Nițipir C
    Curr Oncol; 2023 Feb; 30(2):2457-2464. PubMed ID: 36826148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha.
    Dirican A; Kucukzeybek Y; Erten C; Somali I; Demir L; Can A; Payzin KB; Bayoglu IV; Akyol M; Yildiz Y; Koeseoglu M; Alacacioglu A; Tarhan MO
    Asian Pac J Cancer Prev; 2013; 14(3):2101-5. PubMed ID: 23679326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated neutrophil-lymphocyte ratio combined with hyponatremia indicate poor prognosis in renal cell carcinoma.
    Pedersen MM; Donskov F; Pedersen L; Zhang ZF; Nørgaard M
    Acta Oncol; 2020 Jan; 59(1):13-19. PubMed ID: 31448981
    [No Abstract]   [Full Text] [Related]  

  • 12. NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Young M; Tapia JC; Szabados B; Jovaisaite A; Jackson-Spence F; Nally E; Powles T
    Clin Genitourin Cancer; 2024 Jun; 22(3):102072. PubMed ID: 38615487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy.
    Templeton AJ; Knox JJ; Lin X; Simantov R; Xie W; Lawrence N; Broom R; Fay AP; Rini B; Donskov F; Bjarnason GA; Smoragiewicz M; Kollmannsberger C; Kanesvaran R; Alimohamed N; Hermanns T; Wells JC; Amir E; Choueiri TK; Heng DY
    Eur Urol; 2016 Aug; 70(2):358-64. PubMed ID: 26924770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma.
    Procopio G; Bamias A; Schmidinger M; Hawkins R; Sánchez AR; Estevez SV; Srihari N; Kalofonos H; Bono P; Pisal CB; Hirschberg Y; Dezzani L; Ahmad Q; Rodriguez CS; Jonasch E
    Clin Genitourin Cancer; 2019 Jun; 17(3):e526-e533. PubMed ID: 31196680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Systemic Inflammatory Biomarkers in Patients with Metastatic Renal Cell Carcinoma.
    Nader Marta G; Isaacsson Velho P; Bonadio RRC; Nardo M; Faraj SF; de Azevedo Souza MCL; Muniz DQB; Bastos DA; Dzik C
    Pathol Oncol Res; 2020 Oct; 26(4):2489-2497. PubMed ID: 32583330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma?
    Cetin B; Berk V; Kaplan MA; Afsar B; Tufan G; Ozkan M; Isikdogan A; Benekli M; Coskun U; Buyukberber S
    Clin Genitourin Cancer; 2013 Jun; 11(2):141-8. PubMed ID: 23083797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic model for overall survival that includes the combination of platelet count and neutrophil-lymphocyte ratio within the first six weeks of sunitinib treatment for metastatic renal cell carcinoma.
    Sato MT; Ida A; Kanda Y; Takano K; Ohbayashi M; Kohyama N; Morita J; Fuji K; Sasaki H; Ogawa Y; Kogo M
    BMC Cancer; 2022 Nov; 22(1):1214. PubMed ID: 36434552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Disagreement Between Two Risk Group Models on Prognosis in Patients With Metastatic Renal-Cell Carcinoma.
    Okita K; Hatakeyama S; Tanaka T; Ikehata Y; Tanaka T; Fujita N; Ishibashi Y; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Masumori N; Kitamura H; Ohyama C
    Clin Genitourin Cancer; 2019 Jun; 17(3):e440-e446. PubMed ID: 30772204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
    Rini BI; Hutson TE; Figlin RA; Lechuga MJ; Valota O; Serfass L; Rosbrook B; Motzer RJ
    Clin Genitourin Cancer; 2018 Aug; 16(4):298-304. PubMed ID: 29853320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry.
    Kim JK; Kim SH; Song MK; Joo J; Seo SI; Kwak C; Jeong CW; Song C; Hwang EC; Seo IY; Lee H; Hong SH; Park JY; Chung J
    Cancer Res Treat; 2019 Apr; 51(2):758-768. PubMed ID: 30189720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.